WESTON, Fla., Sept. 27, 2016 /PRNewswire/ -- Apotex Corp. announced today that it has re-entered the market with Ofloxacin Otic Solution 0.3%, the generic equivalent of Floxin Otic®.
Apotex's Ofloxacin Otic Solution 0.3% is now available in 5mL and 10mL.
Re-entering the market with Ofloxacin Otic Solution 0.3% is just another example of how Apotex is everywhere. Making a difference. One life at a time.
Product safety and prescribing information can be found at www.apotexcorp.com.
Apotex Inc. is the 7th largest generic pharmaceutical company globally (according to IMS Health) with over 10,500 employees and estimated sales of approximately $2 billion. The company's US headquarters is based in Weston, Florida. With worldwide manufacturing sites, Apotex can produce up to 24 billion dosages per year. The majority of Apotex sites, including manufacturing, are in North America. Apotex produces 300 medicines in 4,000 dosages and formats that are exported to 115 countries. Apotex has 500 products under development and will spend $2 billion over the next 10 years on research and development.
For more information please visit us at www.apotexcorp.com or
Steve Giuli, Vice President Government Affairs and Trade Relations
*Floxin Otic® is a registered trademark of Alvogen Malta Operations Ltd private limited company MALTA
This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/apotex-ofloxacin-otic-solution-03-generic-version-of-floxin-otic-now-available-300334369.html
SOURCE Apotex Corp